 "Nifty Pharma index up for fifth straight day; Sun Pharma up 14% in a week")
Shares of pharmaceutical companies were trading higher for the fifth straight trading day with Nifty Pharma index gaining 8% as compared to 2% rise in the Nifty 50 index.
Sun Pharmaceutical Industries, Marksans Pharma, Alembic Pharmaceuticals, Caplin Point Laboratories, Ajanta Pharma, Bliss GVS Pharma, Granules India, Aurobindo Pharma and Wockhardt have risen in the range of 10% to 30% in past one week.
On Tuesday, Lupin, Divis Laboratories, Dr Reddy’s Laboratories, Aurobindo Pharma, Sun Pharma, Cadila Healthcare, Cipla and Glenmark Pharmaceuticals were trading higher in the range of 1% to 3% on the National Stock Exchange (NSE).
At 10:15 am; Nifty Pharma index, the largest gainer among sectoral indices, was up 1.8% as compared to 0.37% gain in the benchmark Nifty 50.
Sun Pharma was up nearly 2% at Rs 545 on Tuesday, gaining 14% in past one week on report that the US regulator has upgraded current status of the company’s Halol plant to VAI (Voluntary Action Indicated).
“We are awaiting the receipt of the Establishment Inspection Report (EIR) from the US FDA for the above referred GMP inspection conducted at our Halol facility from February 12-23, 2018. As and when we receive the EIR, we shall inform the exchanges immediately,” Sun Pharma said on a clarification on news report.
The upgradation status of the plant means that the response and remediation works of Sun Pharma are at satisfactory level of USFDA and critical issues in the company are virtually resolved, analyst at Prabhudas Lilladher said event update.
The VAI status will open opportunity of receiving new approvals for US markets as USFDA will now start active consideration of the pending applications from Halol plant. We expect approvals of old ANDAs in near term due to large dependence on Halol plant among the pending approvals, the brokerage firm said in a report.
Aurobindo Pharma was up 3% to Rs 592, extending its past two days 5% gain, due to US FDA approval for gOmeprazole and classification of its Unit-IV as VAI.
Reliance Securities expect Aurobindo Pharma’s US business to clock 11% CAGR over FY18-20E led by new launches (30-40 in FY19 including few niche products) and ramp-up in injectable biz.
With double-digit margin in European business, we expect further improvement in margin led by transfer of products from Europe to Indian units for manufacturing (transferred 83 products out of planned 112); the brokerage firm said in a note and maintains fundamental BUY recommendation on the stock with target price of Rs 712.
Sun Pharmaceutical Industries, Marksans Pharma, Alembic Pharmaceuticals, Caplin Point Laboratories, Ajanta Pharma, Bliss GVS Pharma, Granules India, Aurobindo Pharma and Wockhardt have risen in the range of 10% to 30% in past one week.
On Tuesday, Lupin, Divis Laboratories, Dr Reddy’s Laboratories, Aurobindo Pharma, Sun Pharma, Cadila Healthcare, Cipla and Glenmark Pharmaceuticals were trading higher in the range of 1% to 3% on the National Stock Exchange (NSE).
At 10:15 am; Nifty Pharma index, the largest gainer among sectoral indices, was up 1.8% as compared to 0.37% gain in the benchmark Nifty 50.
Sun Pharma was up nearly 2% at Rs 545 on Tuesday, gaining 14% in past one week on report that the US regulator has upgraded current status of the company’s Halol plant to VAI (Voluntary Action Indicated).
“We are awaiting the receipt of the Establishment Inspection Report (EIR) from the US FDA for the above referred GMP inspection conducted at our Halol facility from February 12-23, 2018. As and when we receive the EIR, we shall inform the exchanges immediately,” Sun Pharma said on a clarification on news report.
The upgradation status of the plant means that the response and remediation works of Sun Pharma are at satisfactory level of USFDA and critical issues in the company are virtually resolved, analyst at Prabhudas Lilladher said event update.
The VAI status will open opportunity of receiving new approvals for US markets as USFDA will now start active consideration of the pending applications from Halol plant. We expect approvals of old ANDAs in near term due to large dependence on Halol plant among the pending approvals, the brokerage firm said in a report.
Aurobindo Pharma was up 3% to Rs 592, extending its past two days 5% gain, due to US FDA approval for gOmeprazole and classification of its Unit-IV as VAI.
Reliance Securities expect Aurobindo Pharma’s US business to clock 11% CAGR over FY18-20E led by new launches (30-40 in FY19 including few niche products) and ramp-up in injectable biz.
With double-digit margin in European business, we expect further improvement in margin led by transfer of products from Europe to Indian units for manufacturing (transferred 83 products out of planned 112); the brokerage firm said in a note and maintains fundamental BUY recommendation on the stock with target price of Rs 712.
| COMPANY | LATEST | 1-WEEK BEFORE | GAIN(%) |
| CAPLIN POINT LAB | 467.40 | 360.85 | 29.53 |
| ALEMBIC PHARMA | 528.75 | 415.90 | 27.13 |
| MARKSANS PHARMA | 30.40 | 24.70 | 23.08 |
| SUVEN LIFE SCIE. | 221.85 | 185.80 | 19.40 |
| SUN PHARMA.INDS. | 540.10 | 473.65 | 14.03 |
| AJANTA PHARMA | 1026.00 | 911.05 | 12.62 |
| BLISS GVS PHARMA | 186.00 | 165.90 | 12.12 |
| GRANULES INDIA | 80.55 | 73.00 | 10.34 |
| AUROBINDO PHARMA | 589.55 | 536.35 | 9.92 |
| WOCKHARDT | 701.15 | 639.15 | 9.70 |
| LUPIN | 829.15 | 758.50 | 9.31 |
| DR REDDY'S LABS | 2132.20 | 1959.60 | 8.81 |
| IPCA LABS. | 702.05 | 646.30 | 8.63 |
| GLENMARK PHARMA. | 571.10 | 529.60 | 7.84 |
| CADILA HEALTH. | 373.50 | 348.65 | 7.13 |
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%